CXCL13 and benign prostatic hyperplasia: These findings uncover a critical immune surveillance mechanism in BPH and suggest that targeting the CXCL13-CD4<sup>+</sup> T cell axis may offer a novel therapeutic strategy for age-related prostate enlargement.